Published in Blood on July 18, 2011
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol (2012) 1.20
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One (2012) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One (2013) 1.07
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 1.07
Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother (2013) 1.06
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 1.05
Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol (2012) 1.05
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology (2014) 1.03
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol (2013) 0.97
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother (2015) 0.95
Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial". Neuro Oncol (2014) 0.89
Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol (2014) 0.88
Regulatory T cells move in when gliomas say "I Do". Clin Cancer Res (2012) 0.85
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res (2014) 0.83
Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med (2013) 0.81
Targeting the right regulatory T-cell population for tumor immunotherapy. Oncoimmunology (2012) 0.81
Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode. PLoS One (2013) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology (2014) 0.80
Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front Oncol (2014) 0.79
Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression. Curr Pathobiol Rep (2013) 0.79
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int (2015) 0.78
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother (2016) 0.75
Immunological Evasion in Glioblastoma. Biomed Res Int (2016) 0.75
Complete response to temozolomide in chronic lymphocytic leukemia. Clin Case Rep (2017) 0.75
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin Cancer Res (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87
Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 7.67
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90
Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 4.58
Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol (2006) 4.26
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest (2002) 3.41
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 1.94
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity (2010) 1.77
Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A (2002) 1.70
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
HCMV microinfections in inflammatory diseases and cancer. J Clin Virol (2007) 1.52
Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol (2006) 1.51
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 1.48
CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A (2011) 1.47
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol (2009) 1.36
The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol (2002) 1.30
Regulatory CD4+CD25+Foxp3+ T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells. J Immunol (2008) 1.27
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood (2009) 1.15
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol (2005) 1.06
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest (2007) 0.99
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol (2009) 0.95
H-2Kb transfection of B16 melanoma cells results in reduced tumourigenicity and metastatic competence. J Immunogenet (1990) 0.94
Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res (2009) 0.93
Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol (2004) 0.78
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol (2005) 6.49
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol (2007) 4.42
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (2002) 3.23
Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature (2010) 3.20
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet (2010) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs (2009) 2.90
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Impact of PhD training on scholarship in a neurosurgical career. J Neurosurg (2013) 2.59
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32